INNOMEDICA LAUNCHES COVID-19 VACCINE PROJECT
Based on the patented liposome technology, InnoMedica has initiated a corona vaccine project and assumes its responsibility as a Swiss pharmaceutical company with in-house pharmaceutical production in order to contribute with its know-how to the development of a vaccine. Find out more about this project.
InnoMedica is currently financing the development of the vaccine project from its own funds and plans a public capital increase in April for further financing.
Request documents now.
PHARMACEUTICALS EFFICIENTLY TARGETED
WITH TALIDOX® INNOMEDICA INTRODUCES A NEW DRUG DELIVERY SYSTEM IN ONCOLOGY AND EXPANDS THE PIPELINE WITH AN INNOVATIVE PARKINSON’S DRUG
Chemotherapy today is still the most common form of medication for the treatment of cancer patients. Due to the life-threatening nature of the disease, doctors often use the highest possible dose. This leads to severe side effects that are often hard to bear for the patient. Using the innovative technology of the liposomal drug delivery system, InnoMedica improves the current systemic application practice and thus reaches a higher drug concentration in the tumor tissue, which enhances the therapeutic effect and at the same time significantly reduces the side effects.
This drug delivery system can be used as a platform technology for other applications: With Talineuren, InnoMedica is developing a new pipeline product pursuing a regenerative therapy approach for Parkinson’s disease, thus opening up the field of neurodegenerative diseases. Depending on the design of the transport system and the selected active agent, different therapies can be improved by InnoMedica’s nanotechnology (eg encephalitis, retinochoroiditis, arthritis, rheumatism, atherosclerosis, etc.). InnoMedica has several national and international research collaborations for the development of more applications.